Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mehy.2005.12.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Axillary Reverse Mapping in Patients Undergoing Axillary Lymph Node Dissection: A Single Institution Experience From India.
Cureus
July 2021
Surgical Oncology, Medica Cancer Hospital, Rangapani, IND.
Introduction Axillary lymph node dissection (ALND) remains the gold standard for clinically node-positive and sentinel node biopsy (SLNB) positive breast cancer patients, but it is associated with the debilitating morbidity of lymphedema. Recently, a new technique of axillary reverse mapping (ARM) has been described which helps in differentiating arm lymphatics from breast lymphatics. Aim To evaluate the applicability of the ARM technique with blue dye and the incidence of metastases in ARM nodes in the Indian population.
View Article and Find Full Text PDFCell morphology impact on the set-up of electroporation protocols for in-suspension and adhered breast cancer cells.
Electromagn Biol Med
October 2020
Departamento De Ingeniería Eléctrica, Centro De Investigación Y De Estudios Avanzados Del Instituto Politécnico Nacional (CINVESTAV) , Mexico City, México.
In order to establish cancer-type-specific electroporation protocols for breast cancer, electroporation was performed in two modalities: in-suspension and adhered cells. Electroporation of cell suspensions was carried out through commercial electroporation cuvettes whereas a novel electrode for electroporation of adhered cells was designed and manufactured aimed to preserve cell structure, to provide a closer model to an scenario, and as a means to visualize the mechanical effects of electroporation on the cell membrane by using scanning electron microscopy. Electroporation protocols and electric field thresholds were predicted and experimentally tuned through propidium iodide uptake and cell viability.
View Article and Find Full Text PDFAntibody-directed metal-organic framework nanoparticles for targeted drug delivery.
Acta Biomater
February 2020
Moscow Institute of Physics and Technology (National Research University), 9 Institutskii per., 141700, Dolgoprudny, Moscow Region, Russia; Sirius University of Science and Technology, 1 Olympic Ave, 354340, Sochi, Russia. Electronic address:
Nanosized metal-organic frameworks (nMOFs) have shown great promise as high-capacity carriers for a variety of applications. For biomedicine, numerous nMOFs have been proposed that can transport virtually any molecular drug, can finely tune their payload release profile, etc. However, perspectives of their applications for the targeted drug delivery remain relatively unclear.
View Article and Find Full Text PDFA non-covalent antibody complex for the delivery of anti-cancer drugs.
Eur J Pharm Biopharm
September 2019
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy; Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address:
Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important impact on their activity, characterization, and manufacturing. A new antibody drug delivery system (ADS) based on a non-covalent linkage between a Fc-binding protein, in this case Protein A or Protein G, and a mAb was investigated in the effort to achieve greater homogeneity and to create a versatile and adaptable drug delivery system. Recombinant staphylococcal Protein A and streptococcal Protein G were chemically PEGylated at the N-terminus with a 5 kDa and a 20 kDa PEG, respectively, yielding two monoconjugates with a mass of ≈50 and ≈45 kDa.
View Article and Find Full Text PDFEstrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification.
Am J Surg Pathol
September 2019
Departments of Breast Oncology.
Overexpression of human epidermal growth factor receptor 2 (HER2) protein is well known to be more frequent in ductal carcinoma in situ (DCIS) than in invasive ductal carcinoma (IDC). However, the reasons for this difference are poorly understood. On the basis of the high frequency of estrogen receptor-positive (ER+) and HER2-positive (HER2+) DCIS, we hypothesized that this tumor type overexpresses HER2 protein without gene amplification and retrospectively investigated the HER2/neu gene status of 71 ER(+)HER2(+) DCIS, surgically removed during the 2007 to 2017 period, employing fluorescence in situ hybridization (FISH).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!